New insider activity at Teva Pharmaceutical ( (TEVA) ) has taken place on December 11, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
In recent transactions involving Teva Pharmaceutical stock, Richard Daniell, the Executive Vice President of European Commercial, sold 115,468 shares, amounting to $3,310,467. Meanwhile, Mark Sabag, the Executive Vice President of International Markets Commercial, sold 216,892 shares, totaling $6,229,549.
Recent Updates on TEVA stock
Teva Pharmaceutical Industries Limited recently announced an extension of its Revolving Facility Agreement’s maturity date from April 2027 to April 2028, along with amendments to financial covenants like the maximum permitted leverage ratio and conditions related to Investment Grade Status. These changes are aimed at enhancing the company’s financial flexibility and operational strategy. Despite strong technical momentum and positive earnings call insights, analysts have expressed concerns over financial challenges and valuation, emphasizing the importance of debt reduction and profitability improvement for future stability.
Spark’s Take on TEVA Stock
According to Spark, TipRanks’ AI Analyst, TEVA is a Neutral.
Teva’s overall stock score reflects a company in transition. Strong technical momentum and positive earnings call insights are offset by financial challenges and valuation concerns. Continued focus on debt reduction and profitability improvement is crucial for future stability.
To see Spark’s full report on TEVA stock, click here.
More about Teva Pharmaceutical
YTD Price Performance: 39.91%
Average Trading Volume: 11,343,851
Technical Sentiment Signal: Buy
Current Market Cap: $33.02B